DOCSLIB.ORG

Animal Models of Schizophrenia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Animal Models of Schizophrenia British Journal of DOI:10.1111/j.1476-5381.2011.01386.x www.brjpharmacol.org BJP Pharmacology Themed Issue: Translational Neuropharmacology – Using Appropriate Animal Models to Guide Clinical Drug Development Correspondence Professor Kevin Fone, School of Biomedical Sciences, Medical School, Queen’s Medical Centre, REVIEWbph_1386 1162..1194 The University of Nottingham, Nottingham NG7 2UH, UK. E-mail: Animal models of [email protected] ---------------------------------------------------------------- Keywords schizophrenia schizophrenia; animal model; antipsychotics; isolation rearing; ventral hippocampal lesion; CA Jones, DJG Watson and KCF Fone reelin; DISC-1; neuregulin; dysbindin; phencyclidine School of Biomedical Sciences, Medical School, Queen’s Medical Centre, The University of ---------------------------------------------------------------- Nottingham, Nottingham, UK Received 23 November 2010 Revised 9 March 2011 Accepted 12 March 2011 Developing reliable, predictive animal models for complex psychiatric disorders, such as schizophrenia, is essential to increase our understanding of the neurobiological basis of the disorder and for the development of novel drugs with improved therapeutic efficacy. All available animal models of schizophrenia fit into four different induction categories: developmental, drug-induced, lesion or genetic manipulation, and the best characterized examples of each type are reviewed herein. Most rodent models have behavioural phenotype changes that resemble ‘positive-like’ symptoms of schizophrenia, probably reflecting altered mesolimbic dopamine function, but fewer models also show altered social interaction, and learning and memory impairment, analogous to negative and cognitive symptoms of schizophrenia respectively. The negative and cognitive impairments in schizophrenia are resistant to treatment with current antipsychotics, even after remission of the psychosis, which limits their therapeutic efficacy. The MATRICS initiative developed a consensus on the core cognitive deficits of schizophrenic patients, and recommended a standardized test battery to evaluate them. More recently, work has begun to identify specific rodent behavioural tasks with translational relevance to specific cognitive domains affected in schizophrenia, and where available this review focuses on reporting the effect of current and potential antipsychotics on these tasks. The review also highlights the need to develop more comprehensive animal models that more adequately replicate deficits in negative and cognitive symptoms. Increasing information on the neurochemical and structural CNS changes accompanying each model will also help assess treatments that prevent the development of schizophrenia rather than treating the symptoms, another pivotal change required to enable new more effective therapeutic strategies to be developed. LINKED ARTICLES This article is part of a themed issue on Translational Neuropharmacology. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.164.issue-4 Abbreviations 5-HT6, 5-hydroxytryptamine6 receptor; BDNF, brain-derived neurotrophic factor; D2, dopamine D2 receptor; DISC-1, disrupted-in-schizophrenia 1; DTNBP1, dystobrevin-binding protein 1; EGF, epidermal growth factor; GAD65, glutamic acid decarboxylase enzyme 65 kDa isoform; GAD67, glutamic acid decarboxylase enzyme 67 kDa isoform; GAT-1, GABA transporter 1; GD, gestational day; GLAST, glutamate–aspartate transporter; Ig, immunoglobulin; LPS, lipopolysaccharide; MAM, methylazoxymethanol; NAA, N-acetylaspartic acid; nAcc, nucleus accumbens; NAAG, N-acetylaspartylglutamate; NGF, nerve growth factor; NMDA, N-methyl-D-aspartic acid; NRG1, neuregulin 1; PCP, phencyclidine; PFc, prefrontal cortex; PND, postnatal day; PPI, prepulse inhibition of acoustic startle; vHip, ventral hippocampal; VTA, ventral tegmental area Introduction (including auditory and visual hallucinations, delusions, con- ceptual disorganization and thought disorder), negative Schizophrenia is a chronic debilitating neuropsychiatric dis- (emotional blunting, social withdrawal, anhedonia, avoli- order affecting approximately 1% of the population world- tion, poverty of thought and content of speech) and cogni- wide. Symptoms cluster into three categories: positive tive dysfunction (including impaired executive function, 1162 British Journal of Pharmacology (2011) 164 1162–1194 © 2011 The Authors British Journal of Pharmacology © 2011 The British Pharmacological Society Animal models of schizophrenia BJP working memory and attention) (Andreasen, 1995). Patients phrenia which have to be treated to meet therapeutic needs, present with extremely heterogeneous symptom combina- and recommended a specific neuropsychological test battery tions, making diagnosis and treatment problematic. Many to characterize these domains. A development of this initia- patients undergo prolonged periods of remission interspersed tive is the evaluation of the clinical relevance and predictive with relapses of psychotic episodes. Disease onset is typically value of existing preclinical cognitive tasks and agreement for post adolescence (16–25 years), with a higher incidence of the need to develop a preclinical cognitive test battery to aid psychotic symptoms in males and a bimodal later onset drug development (Hagan and Jones, 2005; Nuechterlein (40–60 years) in females. Although the aetiology of schizo- et al., 2005). Floresco et al. (2005) suggested using two phrenia remains contentious, it is a multifactorial neurode- approaches in experimental animals: lesions or drugs to velopmental disorder influenced by both genetic and manipulate specific systems altered in schizophrenia and environmental factors (Lewis and Lieberman, 2000; van Os developing models with cognitive deficits that resemble those et al., 2010), such that monozygotic siblings of affected indi- seen in the disorder, to improve translational reliability of viduals show a 50–80% risk of developing the disorder. data obtained. Young et al. (2009) extensively reviewed exist- The first drugs, found by serendipity rather than design in ing animal cognitive paradigms and critically appraised their the 1950s, to treat the psychotic symptoms of schizophrenia translational relevance to the seven human cognitive (haloperidol and chlorpromazine, called classical neurolep- domains identified as being affected in schizophrenia. tics) are also known as the first-generation antipsychotics. However, such cognitive paradigms need to be examined, not The second-generation or atypical antipsychotics, so called just in normal healthy animals, but in credible validated because of their different clinical profile (including clozapine, models of the disorder which will be reviewed in this paper. olanzepine, risperidone and aripiprazole) developed from the Animal models of complex heterogeneous psychiatric dis- 1970s have less tendency to produce unwanted extrapyrami- orders are clearly very valuable preclinical tools with which to dal side effects and hyperprolactinaemia (Remington, 2003). investigate the neurobiological basis of the disorder. They offer While first-generation antipsychotics are classified according a more rapid platform to monitor disease progression than in to chemical structure, the second-generation antipsychotics humans, and the opportunity to perform invasive monitoring are characterized according to their pharmacology. These of structural and molecular changes that underlie the cause of drugs were developed to treat the positive (psychotic) symp- the disease and test novel therapeutics not possible in patients. toms and not the negative or cognitive impairments. However, a perplexing problem is how to assess some of the However, multi-site, double-blind studies comparing several core symptoms of psychiatric disorders (like thoughts, and second-generation antipsychotics with a typical antipsy- verbal learning and memory), which are uniquely human chotic, perphenazine, failed to substantiate any major thera- traits (Powell and Miyakawa, 2006). In general, most behav- peutic advantage of the former (Lieberman et al., 2005). The iours can only be indexed rather than directly quantified, and cognitive symptoms of schizophrenia often precede the we are left to monitor performance in tasks designed to have occurrence of psychosis, and their treatment is considered a translational relevance to core symptoms and make inference better predictor of therapeutic outcome (Mintz and Kopelow- about the psychiatric state. A further problem with models of icz, 2007). However, while positive symptoms are currently schizophrenia is that there is no current ‘gold standard’ medi- treated to a varying degree by typical and atypical anti- cation available to treat all the symptoms that can be used as psychotics, the negative, and in particular, the cognitive a definitive positive control in preclinical studies, although impairments, remain resistant to treatment with current drugs like haloperidol and clozapine should reverse behav- antipsychotics even after remission of the psychosis ioural correlates of positive symptoms. Furthermore, many of (Nuechterlein et al., 2004; Keefe et al., 2007; Mintz and the current antipsychotics may have a small therapeutic Kopelowicz, 2007). Consequently, there is an urgent need to window of effect before sedation and other non-specific motor develop novel compounds that demonstrate increased effi- suppressant actions confound interpretation in tasks designed cacy against cognitive dysfunction and
Load more

Recommended publications
  • Prevention Or Amelioration of Autism-Like Symptoms in Animal Models: Will It Bring Us Closer to Treating Human ASD?
    International Journal of Molecular Sciences Review Prevention or Amelioration of Autism-Like Symptoms in Animal Models: Will it Bring Us Closer to Treating Human ASD? Asher Ornoy 1,* , Liza Weinstein-Fudim 1 and Zivanit Ergaz 1,2 1 Laboratory of Teratology, Department of Medical Neurobiology, Hebrew University Hadassah Medical School, Jerusalem 9112001, Israel; [email protected] 2 Neonatology Department, Hadassah Hebrew University Medical Center, Jerusalem 9112001, Israel; [email protected] * Correspondence: [email protected]; Tel.: +972-2-6758329 Received: 17 February 2019; Accepted: 23 February 2019; Published: 1 March 2019 Abstract: Since the first animal model of valproic acid (VPA) induced autistic-like behavior, many genetic and non-genetic experimental animal models for Autism Spectrum Disorder (ASD) have been described. The more common non-genetic animal models induce ASD in rats and mice by infection/inflammation or the prenatal or early postnatal administration of VPA. Through the establishment of these models, attempts have been made to ameliorate or even prevent ASD-like symptoms. Some of the genetic models have been successfully treated by genetic manipulations or the manipulation of neurotransmission. Different antioxidants have been used (i.e., astaxanthin, green tea, piperine) to reduce brain oxidative stress in VPA-induced ASD models. Agents affecting brain neurotransmitters (donepezil, agmatine, agomelatine, memantine, oxytocin) also successfully reduced ASD-like symptoms. However, complete prevention of the development of symptoms was achieved only rarely. In our recent study, we treated mouse offspring exposed on postnatal day four to VPA with S-adenosine methionine (SAM) for three days, and prevented ASD-like behavior, brain oxidative stress, and the changes in gene expression induced by VPA.
    [Show full text]
  • NMDA Receptors Containing the Glun2d Subunit Control Neuronal Function in the Subthalamic Nucleus
    The Journal of Neuroscience, December 2, 2015 • 35(48):15971–15983 • 15971 Cellular/Molecular NMDA Receptors Containing the GluN2D Subunit Control Neuronal Function in the Subthalamic Nucleus X Sharon A. Swanger,1* Katie M. Vance,1* Jean-Franc¸ois Pare,3 Florence Sotty,4 Karina Fog,4 Yoland Smith,2,3 and X Stephen F. Traynelis1 1Department of Pharmacology and 2Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30322, 3Yerkes National Primate Research Center and Morris K. Udall Center of Excellence for Parkinson’s Disease Research, Emory University, Atlanta, Georgia 30329, and 4H. Lundbeck A/S, Division of Neurodegeneration and Biologics, Ottiliavej 9, DK-2500 Valby, Denmark The GluN2D subunit of the NMDA receptor is prominently expressed in the basal ganglia and associated brainstem nuclei, including the subthalamic nucleus (STN), globus pallidus, striatum, and substantia nigra. However, little is known about how GluN2D-containing NMDA receptors contribute to synaptic activity in these regions. Using Western blotting of STN tissue punches, we demonstrated that GluN2D is expressed in the rat STN throughout development [age postnatal day 7 (P7)–P60] and in the adult (age P120). Immunoelectron microscopy of the adult rat brain showed that GluN2D is predominantly expressed in dendrites, unmyelinated axons, and axon terminals within the STN. Using subunit-selective allosteric modulators of NMDA receptors (TCN-201, ifenprodil, CIQ, and DQP-1105), we provide evidence that receptors containing the GluN2B and GluN2D subunits mediate responses to exogenously applied NMDA and glycine, as well as synaptic NMDA receptor activation in the STN of rat brain slices. EPSCs in the STN were mediated primarily by AMPA and NMDA receptors and GluN2D-containing NMDA receptors controlled the slow deactivation time course of EPSCs in the STN.
    [Show full text]
  • GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine
    Neuropsychopharmacology (2017) 42, 1231–1242 © 2017 American College of Neuropsychopharmacology. All rights reserved 0893-133X/17 www.neuropsychopharmacology.org GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine 1,5 1,5 1,2 1 1 1 Rong-Jian Liu , Catharine Duman , Taro Kato , Brendan Hare , Dora Lopresto , Eunyoung Bang , 3 3,4 1 1 *,1 Jeffery Burgdorf , Joseph Moskal , Jane Taylor , George Aghajanian and Ronald S Duman 1Departments of Psychiatry and Neurosciences, Yale University School of Medicine, New Haven, CT, USA; 2Sumitomo Dainippon Pharma Co, Suita, 3 Osaka, Japan; Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, Northwestern University, Evanston IL, USA; 4 Naurex, Inc., Evanston, IL, USA GLYX-13 is a putative NMDA receptor modulator with glycine-site partial agonist properties that produces rapid antidepressant effects, but without the psychotomimetic side effects of ketamine. Studies were conducted to examine the molecular, cellular, and behavioral actions of GLYX-13 to further characterize the mechanisms underlying the antidepressant actions of this agent. The results demonstrate that a single dose of GLYX-13 rapidly activates the mTORC1 pathway in the prefrontal cortex (PFC), and that infusion of the selective mTORC1 inhibitor rapamycin into the medial PFC (mPFC) blocks the antidepressant behavioral actions of GLYX-13, indicating a requirement for mTORC1 similar to ketamine. The results also demonstrate that GLYX-13 rapidly increases the number and function of spine synapses in the apical dendritic tuft of layer V pyramidal neurons in the mPFC. Notably, GLYX-13 significantly increased the synaptic responses to hypocretin, a measure of thalamocortical synapses, compared with its effects on 5-HT responses, a measure of cortical- cortical responses mediated by the 5-HT receptor.
    [Show full text]
  • A Systematic Review of Performance-Enhancing Pharmacologicals and Biotechnologies in the Army
    Bond University Research Repository A systematic review of performance-enhancing pharmacologicals and biotechnologies in the Army Ko, Henry ; Hunter, K E; Scott, A M; Ayson, Mark; Willson, M L Published in: Journal of the Royal Army Medical Corps DOI: 10.1136/jramc-2016-000752 Licence: CC BY-NC Link to output in Bond University research repository. Recommended citation(APA): Ko, H., Hunter, K. E., Scott, A. M., Ayson, M., & Willson, M. L. (2018). A systematic review of performance- enhancing pharmacologicals and biotechnologies in the Army. Journal of the Royal Army Medical Corps, 164(3). https://doi.org/10.1136/jramc-2016-000752 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator. Download date: 06 Oct 2021 ABSTRACT Introduction: In 2015, the Australian Army commissioned a systematic review to assess the evidence on effectiveness and safety of pharmacological and biotechnological products for cognitive enhancement specifically in Army personnel. Methods: Searches for studies examining biotechnological and pharmacological products in Army populations were conducted in December 2015. Cochrane CENTRAL, MEDLINE, EMBASE, CINAHL and PsycINFO were searched; no date or language restrictions were applied. WHO’s International Clinical Trials Registry Platform and ClinicalTrials.gov were searched to identify ongoing trials. Studies meeting inclusion criteria were evaluated for risk of bias using the Cochrane Risk of Bias tool.
    [Show full text]
  • Novel Therapeutic Strategies in Parkinson's Disease
    Novel therapeutic strategies in Parkinson’s disease Peter Klivenyi, Laszlo Vecsei To cite this version: Peter Klivenyi, Laszlo Vecsei. Novel therapeutic strategies in Parkinson’s disease. European Journal of Clinical Pharmacology, Springer Verlag, 2009, 66 (2), pp.119-125. 10.1007/s00228-009-0742-4. hal-00535002 HAL Id: hal-00535002 https://hal.archives-ouvertes.fr/hal-00535002 Submitted on 11 Nov 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Eur J Clin Pharmacol (2010) 66:119–125 DOI 10.1007/s00228-009-0742-4 REVIEW ARTICLE Novel therapeutic strategies in Parkinson’s disease Peter Klivenyi & Laszlo Vecsei Received: 30 June 2009 /Accepted: 30 September 2009 /Published online: 16 October 2009 # Springer-Verlag 2009 Introduction producing symptomatic benefit. However, in the subse- quent human clinical trials, many of them failed to produce Parkinson’s disease (PD) is a neurodegenerative disorder the same efficacy as seen in preclinical studies. These characterized by resting tremor, rigidity, and bradykinesia. failures are not necessarily an indication of drug failure or The pathological processes begin years/decades before the drug action but may be related to inadequate administration, first motor symptoms are observed.
    [Show full text]
  • Neurotransmission Product Guide | Edition 1
    Neurotransmission Product Guide | Edition 1 Delphinium Delphinium A source of Methyllycaconitine Contents by Research Area: • Dopaminergic Transmission • Glutamatergic Transmission • Opioid Peptide Transmission • Serotonergic Transmission • Chemogenetics Tocris Product Guide Series Neurotransmission Research Contents Page Principles of Neurotransmission 3 Dopaminergic Transmission 5 Glutamatergic Transmission 6 Opioid Peptide Transmission 8 Serotonergic Transmission 10 Chemogenetics in Neurotransmission Research 12 Depression 14 Addiction 18 Epilepsy 20 List of Acronyms 22 Neurotransmission Research Products 23 Featured Publications and Further Reading 34 Introduction Neurotransmission, or synaptic transmission, refers to the passage of signals from one neuron to another, allowing the spread of information via the propagation of action potentials. This process is the basis of communication between neurons within, and between, the peripheral and central nervous systems, and is vital for memory and cognition, muscle contraction and co-ordination of organ function. The following guide outlines the principles of dopaminergic, opioid, glutamatergic and serotonergic transmission, as well as providing a brief outline of how neurotransmission can be investigated in a range of neurological disorders. Included in this guide are key products for the study of neurotransmission, targeting different neurotransmitter systems. The use of small molecules to interrogate neuronal circuits has led to a better understanding of the under- lying mechanisms of disease states associated with neurotransmission, and has highlighted new avenues for treat- ment. Tocris provides an innovative range of high performance life science reagents for use in neurotransmission research, equipping researchers with the latest tools to investigate neuronal network signaling in health and disease. A selection of relevant products can be found on pages 23-33.
    [Show full text]
  • Neonatal Administration of Memantine Enhances Social Cognition in Adult Rats Subjected to Early Maternal Deprivation
    https://doi.org/10.5607/en.2016.25.6.328 Exp Neurobiol. 2016 Dec;25(6):328-332. pISSN 1226-2560 • eISSN 2093-8144 Original Article Neonatal Administration of Memantine Enhances Social Cognition in Adult Rats Subjected to Early Maternal Deprivation Ezequiel Uribe*, Eduardo Sánchez-Mendoza, Nayadoleni Nieves and Gustavo Merchor Biophysics and Neuroscience Center, Behavioral Neurobiology Laboratory, Biomedical and Technological Sciences, University of Carabobo, Valencia, Venezuela Schizophrenia is considered a neurodevelopmental disorder; however, all the available treatment options are used when the disease becomes clinically significant in adolescence or early adulthood. Using a developmental rat model of schizophrenia, we examined whether neonatal treatment with memantine, an NMDA receptor modulator, can improve schizophrenic-like symptoms in adulthood. Early maternal deprivation in rats produces deficits in social interaction behaviors in adulthood. In contrast, memantine administrated in neonatal rats subjected to early maternal deprivation significantly reduces deficits in social interaction behaviors in adulthood. These results raise the possibility that pharmacological treatment with memantine at the early developmental stage helps people with a risk to develop schizophrenic-like symptoms. Key words: Schizophrenia, neuropharmacology, developing brain, glutamate, social cognition, neonatal INTRODUCTION begin before adolescence but becomes clinically significant in this period; probably during prefrontal cortex maturation [5]. Schizophrenia is considered a neurodevelopmental disorder, SC is a prefrontal function referred to the capacity of identify with onset during adolescence or early adulthood in 80% of cases the mental status about conspecifics, which depend of a correct [1]. It shows no clear signs of behavioral dysfunction during glutamatergic transmission [6], widely impaired in schizophrenia childhood; social isolation is frequent during prodromal period [7].
    [Show full text]
  • Review Article Cell Cycle Inhibition Without Disruption of Neurogenesis Is a Strategy for Treatment of Aberrant Cell Cycle Diseases: an Update
    The Scientific World Journal Volume 2012, Article ID 491737, 13 pages The cientificWorldJOURNAL doi:10.1100/2012/491737 Review Article Cell Cycle Inhibition without Disruption of Neurogenesis Is a Strategy for Treatment of Aberrant Cell Cycle Diseases: An Update Da-Zhi Liu and Bradley P. Ander Department of Neurology and the MIND Institute, University of California at Davis, Sacramento, CA 95817, USA Correspondence should be addressed to Da-Zhi Liu, [email protected] Received 13 October 2011; Accepted 17 November 2011 Academic Editors: F. Bareyre and B. K. Jin Copyright © 2012 D.-Z. Liu and B. P. Ander. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Since publishing our earlier report describing a strategy for the treatment of central nervous system (CNS) diseases by inhibiting the cell cycle and without disrupting neurogenesis (Liu et al. 2010), we now update and extend this strategy to applications in the treatment of cancers as well. Here, we put forth the concept of “aberrant cell cycle diseases” to include both cancer and CNS diseases, the two unrelated disease types on the surface, by focusing on a common mechanism in each aberrant cell cycle reentry. In this paper, we also summarize the pharmacological approaches that interfere with classical cell cycle molecules and mitogenic pathways to block the cell cycle of tumor cells (in treatment of cancer) as well as to block the cell cycle of neurons (in treatment of CNS diseases). Since cell cycle inhibition can also block proliferation of neural progenitor cells (NPCs) and thus impair brain neurogenesis leading to cognitive deficits, we propose that future strategies aimed at cell cycle inhibition in treatment of aberrant cell cycle diseases (i.e., cancers or CNS diseases) should be designed with consideration of the important side effects on normal neurogenesis and cognition.
    [Show full text]
  • NYX-2925 Is a Novel N-Methyl-D-Aspartate Receptor Modulator That Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain
    1521-0103/366/3/485–497$35.00 https://doi.org/10.1124/jpet.118.249409 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:485–497, September 2018 Copyright ª 2018 The Author(s). This is an open access article distributed under the CC BY Attribution 4.0 International license. NYX-2925 Is a Novel N-Methyl-D-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain Nayereh Ghoreishi-Haack, Jessica M. Priebe, Jacqueline D. Aguado, Elizabeth M. Colechio, Jeffrey S. Burgdorf, M. Scott Bowers, Cassia N. Cearley, M. Amin Khan, and Joseph R. Moskal Aptinyx, Inc., Evanston, Illinois (N.G.-H., J.M.P., J.D.A., E.M.C., J.S.B., M.S.B., C.N.C., M.A.K., J.R.M.) and Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, Northwestern University, Evanston, Illinois (J.S.B., M.S.B., Downloaded from J.R.M.) Received April 4, 2018; accepted July 3, 2018 ABSTRACT NYX-2925 [(2S,3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo-2,5- and formalin-induced persistent pain, but was ineffective in jpet.aspetjournals.org diazaspiro[3.4]octan-2-yl)butanamide] is a novel N-methyl-D- the tail flick model. The analgesic effects of NYX-2925 were aspartate (NMDA) receptor modulator that is currently being blocked by the systemic administration of NMDA receptor investigated in phase 2 clinical studies for the treatment of antagonist 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic painful diabetic peripheral neuropathy and fibromyalgia.
    [Show full text]
  • Research Article
    Available Online at http://www.recentscientific.com International Journal of CODEN: IJRSFP (USA) Recent Scientific International Journal of Recent Scientific Research Research Vol. 9, Issue, 6(E), pp. 27560-27565, June, 2018 ISSN: 0976-3031 DOI: 10.24327/IJRSR Research Article BIOSYNTHESIS OF NEUROSTEROID AND PHARMACOLOGYCAL ACTION Vandna Dewangan*., Trilochan Satapthy and Ram Sahu Department of Pharmacology, Columbia Institute of Pharmacy, Tekari, Near Vidhansabha, Raipur-493111(C.G.) India DOI: http://dx.doi.org/10.24327/ijrsr.2018.0906.2285 ARTICLE INFO ABSTRACT Article History: Over the past decade, it has become clear that the brain, like the gonad, adrenal and placenta, is a steroid genic organ. Neurosteroids are synthetized in the central and the peripheral nervous system, Received 20th March, 2018 in glial cells, and also in neurons, from cholesterol or steroidal precursors imported from peripheral Received in revised form 27th sources. However, unlike classic steroid genic tissues, the synthesis of steroids in the nervous April, 2018 system requires the coordinate expression and regulation of the genes encoding the steroid genic Accepted 5th May, 2018 enzymes in several different cell types (neurons and glia) at different locations in the nervous Published online 28th June, 2018 system, and at distances from the cell bodies. The steroids synthesized by the brain and nervous system, given the name neurosteroids Progesterone itself is also a neurosteroid, and a progesterone Key Words: receptor has been detected in peripheral and central glial cells. At different sites in the brain, Neurosteroid, Steroid hormones, neurosteroid concentrations vary according to environmental and behavioural circumstances, such as Progesterone, Glial Cell, Nuclear receptor, stress, sex recognition, or aggressiveness.
    [Show full text]
  • Yale University School of Medicine Human Investigation Committee
    Approved - Valid through 23-JUN-2017 YALE UNIVERSITY SCHOOL OF MEDICINE HUMAN INVESTIGATION COMMITTEE Application to Involve Human Subjects in Research ECTION DMINISTRATIVE NFORMATION S I: A I Title of Research Project: Glutamate-opioid interactions in alcohol drinking behaviors Principal Investigator: Yale Academic Appointment: Suchitra Krishnan-Sarin, Ph.D. Associate Professor Campus Address: S-208, 34 Park Street, New Haven, CT 06519 Campus Phone: Fax: Pager: E-mail: 203-974-7595 203-974-7606 [email protected] Protocol Correspondent Name & Address (if different than PI): Dana Cavallo, 34 Park Street, New Haven CT 06519 Campus Phone: Fax: E-mail: 203-974-7607 203-974-7606 [email protected] Faculty Advisor:(required if PI is a student, tment: resident, fellow or other trainee) N Campus Address: Campus Phone: Fax: Pager: E-mail: SECTION II: GENERAL INFORMATION 1. Performing Organizations: Identify the hospital, in-patient or outpatient facility, school or other agency that will serve as the location of the research. Choose all that apply: a. Internal Location[s] of the Study: Magnetic Resonance Research Center PET Center (MR-TAC) YCCI/Church Street Research Unit (CSRU) Yale Cancer Center YCCI/Hospital Research Unit (HRU) Yale-New Haven Hospital YCCI/Keck Laboratories Specify Other Yale Location Cancer Data Repository/Tumor Registry b. External Location[s]: APT Foundation, Inc. Haskins Laboratories Connecticut Mental Health Center John B. Pierce Laboratory, Inc. Veterans Affairs Hospital, West Haven Other Locations, Specify: CMU c. Additional Required Documents (check all that apply): N/A *YCCI-Scientific and Safety Committee (YCCI-SSC) Approval Date: *Pediatric Protocol Review Committee (PPRC) Approval Date: Page 1 of 52 APPROVED BY THE YALE UNIVERSITY HIC ON 07-DEC-2016 Approved - Valid through 23-JUN-2017 *YCC Protocol Review Committee (YRC-PRC)Approval Date: *Dept.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]